Skip to content

Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes

Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00981929
Enrollment
412
Registered
2009-09-22
Start date
2009-09-30
Completion date
2011-01-31
Last updated
2010-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytochrome P450 Phenotype and Genotype Metrics

Keywords

CYP2D6, CYP2C9, CYP2C19, CYP1A2

Brief summary

The Cytochrome P450 enzymes are responsible for the metabolism of a wide range of drugs and other xenobiotics. Genetic variants of the encoding P450 genes have shown to influence the rate of metabolism of many clinically used drugs. The drugs tramadol, omeprazole, losartan, quinidine and caffeine reflect the activity of CYP2D6 (tramadol), CYP2C19 (omeprazole), CYP2C9 (losartan), CYP1A2 (caffeine) and CYP3A4/5 (quinidine). The aim of the study is to investigate if the cocktail of tramadol, omeprazole, losartan and caffeine can be used to simultaneously determine the activity of CYP2D6, CYP2C19, CYP2C9 and CYP1A2. Furthermore, will the natural occurring 4-beta-hydroxy-cholesterol in the blood be measured as a metric for CYP3A4/5. The study is divided in two. First part will include 12 healthy volunteers and consists of three arms separated by at least one week. In the first arm 50 mg of tramadol will be ingested and urine will be collected for 8 hours. In the second arm 20 mg omeprazole, 25 mg losartan and 200 mg caffeine will be ingested followed by 8 hours urine collection and a blood sample 4 hours after administration of the drugs. In the last arm 50 mg of tramadol, 20 mg omeprazole, 25 mg losartan and 200 mg caffeine will be ingested followed by 8 hours urine collection and a blood sample 4 hours after administration of the drugs. Metabolic ratios will be calculated based on urine and plasma concentrations of the drugs and the relevant metabolites. Relevant genetic variants of the cytochrome P450 encoding genes will be determined. If the metabolic ratios of the drugs are not significantly different between the arms, Second part of the study will be conducted. This part is identical with the last arm and will include a maximum of 400 healthy volunteers: 50 mg of tramadol, 20 mg omeprazole, 25 mg losartan and 200 mg caffeine will be ingested followed by 8 hours urine collection and a blood sample 4 hours after administration of the drugs.

Interventions

DRUGTramadol

50 mg single oral dose

DRUGOmeprazole, losartan, caffeine

20 mg omeprazole 25 mg losartan 200 mg caffeine

DRUGTramadol, omeprazole, losartan, caffeine

50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine

Sponsors

Odense University Hospital
CollaboratorOTHER
University of Southern Denmark
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers, * Written consent, AND * Age 18-65 years old.

Exclusion criteria

* Daily medication, * Alcohol abuse, * Pregnancy, OR * Breastfeeding.

Design outcomes

Primary

MeasureTime frame
Metabolic ratiosJanuary 2011

Secondary

MeasureTime frame
Genetic variantsJanuary 2011

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026